Dr Engel brings to Cytochroma over 20 years of experience in regulatory affairs and quality assurance, and will be responsible for directing all of Cytochroma’s regulatory activities, as well as ensuring that the company has appropriate quality systems in place.
Prior to joining Cytochroma, Dr Engel was vice president of regulatory affairs and clinical quality compliance at Par Pharmaceutical, where he was responsible for the regulatory strategies of both branded and generic pharmaceutical programs.
Charles Bishop, president and CEO of Cytochroma, said: “Steve has a proven track record of successful new drug registrations and post-marketing support, and we are pleased to have an individual of this caliber helping us secure global regulatory approvals for our products.”